Articles tagged "Rejection"

2020 American Transplant Congress
First Report of Successful CD38-Antagonist Daratumumab Augmented Carfilzomib-Based Treatment of Refractory Definite AMR of the Lung Allograft
M. N. Kildea¹, C. R. Ensor¹, J. Kim¹, L. Bogar¹, D. Colella¹, R. D. Davis¹, M. Marschner¹, A. Zeevi², N. Soe¹, C. Gries¹
¹AdventHealth, Orlando, FL, ²University of Pittsburgh, Pittsburgh, PA
*Purpose: Antibody-mediated rejection (AMR) after lung transplant (LT) is associated with early progressive chronic lung allograft dysfunction (CLAD) and death. Therapeutic regimens remain poorly evaluated.…
2020 American Transplant Congress
Transplant and Cardiovascular Outcomes in Renal Transplant Recipients with Different Pre-Transplant Cardiovascular Risk
G. Hsu¹, T. M. Sparkes¹, B. N. Reed², S. E. Gale¹, B. R. Ravichandran¹
¹University of Maryland Medical Center, Baltimore, MD, ²University of Maryland School of Pharmacy, Baltimore, MD
*Purpose: Renal transplant patients have higher cardiovascular (CV) risk compared to their peers. Pre-transplant CV risk factors may be amplified post-transplant, but little is known…
2020 American Transplant Congress
Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction
R. Hod Dvorai¹, R. Lee², P. Muluhngwi², M. Raijmakers³, A. Shetty², A. Tambur², M. Ison²
¹Department of Pathology, SUNY Upstate Medical University, Syracuse, NY, ²Northwestern University, Chicago, IL, ³University of Santiago, Santiago, Chile
*Purpose: To evaluate development of de novo donor specific antibodies (dnDSA) in Renal Transplant Recipients (RTR) with immunosuppression (IS) modulation due to BK viremia (BKV)…
2020 American Transplant Congress
Clinical Outcomes Associated with Long-Term Exposure to Airborne Particulate Pollution in Kidney Transplant Recipients
Y. Kim¹, J. Lee²
¹Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, ²Internal Medicine, Seoul National University Boramae Hospital, Seoul, Korea, Republic of
*Purpose: We aimed to evaluate the relationship of 10-μm particulate matter (PM10) with the risk of graft failure, mortality, and decline of graft function in…
2020 American Transplant Congress
C-Reactive Protein 1-Year Post-Transplant is Associated with Future Development of Coronary Artery Vasculopathy and Rejection in a Pediatric Heart Transplant Cohort
H. J. Tadros, A. H. Bashir, F. J. Fricker, B. A. Pietra, D. Gupta
Congenital Heart Center/Pediatrics, University of Florida, Gainesville, FL
*Purpose: Coronary artery vasculopathy (CAV) is one of the leading causes of mortality beyond 3y post-transplant (OHT). Multiple risk factors are associated with development of…
2020 American Transplant Congress
Prospective Donor-Specific CellUlar Alloresponse Assessment for Immunosuppression MinImization in De Novo Renal Transplantation: Results of a Randomized Controlled Biomarker-Guided Trial
O. Bestard¹, P. Reinke², F. Bemelman³, O. Viklicky⁴, M. Koch⁵, M. Giral⁶, J. Ruiz⁷, B. Banas⁸, E. Crespo¹, M. Meneghini¹, H. Volk⁹, J. Grinyo¹
¹Kidney transplantation Unit, Bellvitge University Hospital- IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain, ²Kidney transplantation Unit, Charité - Universitätsmedizin Berlin, Berlin, Germany, ³Kidney transplantation Unit, Amsterdam Medical Centre, Amsterdam, Netherlands, ⁴Nephrology department, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic, ⁵Department of Hepatobiliary Surgery and Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁶Nephrology, Kidney transplantation Unit, Université de Nantes, Nantes, France, ⁷Nephrology, Hospital Marques de Valdecilla, Santander, Spain, ⁸Kidney transplantation Unit, University Hospital Regensburg, Regensburg, Germany, ⁹Institute for Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
*Purpose: Early immunosuppression minimization is associated with higher rates of BPAR. Preformed donor-specific T-cell alloreactivity (DST) assessed with an IFN-γ ELISPOT assay has shown to…
2020 American Transplant Congress
ATHENA – Patient and Allograft Outcome Differences after Kidney Transplantation – Germany vs. France
F. Thaiss¹, C. Sommerer¹, B. Suwelack¹, D. Dragun¹, I. A. Hauser¹, O. Witzke¹, C. Hugo¹, P. Schenker¹, N. Kamar², P. Merville², I. Kroeger³, M. Junge³, B. Nashan¹
¹Athena, Study Group, Germany, ²Athena, Study Group, France, ³Novartis Pharma GmbH, Nürnberg, Germany
*Purpose: In the ATHENA trial [NCT01843348], efficacy and safety of everolimus in combination with tacrolimus [EVR+TAC] or cyclosporine A [EVR+CyA] vs. TAC and mycophenolic acid…
2020 American Transplant Congress
HLA Molecular Mismatch is an Independent Correlate of T-Cell Mediated Rejection and Potential Prognostic Biomarker in Renal Transplantation
C. Wiebe¹, D. Pochinco², I. W. Gibson³, J. Ho¹, P. Birk⁴, A. Goldberg⁴, M. Karpinski⁵, J. Shaw⁵, R. N. David⁵, P. W. Nickerson¹
¹Medicine and Immunology, University of Manitoba, Winnipeg, MB, Canada, ²Shared Health Services, Winnipeg, MB, Canada, ³Pathology, University of Manitoba, Winnipeg, MB, Canada, ⁴Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada, ⁵Medicine, University of Manitoba, Winnipeg, MB, Canada
*Purpose: HLA molecular mismatch alloimmune risk categorization has correlated with de novo donor-specific antibody (dnDSA) development, however, correlation with T-cell mediated rejection (TCMR) phenotypes is…
2020 American Transplant Congress
Clinical Significance of C4d and HLA-DSA on Post-Transplant Clinical Outcomes in Kidney Transplant Recipients with Antibody-Mediated Rejection
W. Park, O. Kwon, Y. Kim, J. Paek, K. Jin, S. Park, S. Han
Internal Medicine, Keimyung University School of Medicine, Keimyung University Kidney Institute, Daegu, Korea, Republic of
*Purpose: The clinicopathological diagnosis of rejection after kidney transplantation (KT) was well defined by Banff classification. In the diagnosis of antibody-mediated rejection (AMR), the presence…
2020 American Transplant Congress
Single versus Dual Immunosuppression in Liver Transplantation for Autoimmune Liver Diseases
S. Sterling¹, S. Hamel¹, C. Garza¹, I. Feurer², S. Rega², S. Alexopoulos³, M. Izzy⁴
¹Pharmacy, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt Transplant Center, Nashville, TN, ³Liver Transplant Surgery, Vanderbilt Transplant Center, Nashville, TN, ⁴Transplant Hepatology, Vanderbilt Transplant Center, Nashville, TN
*Purpose: There is limited evidence on the optimal maintenance immunosuppression after liver transplant (LT) for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and autoimmune…